Mometasone Eg (Mometasone Furoate)

Mometasone Furoate binds to glucocorticoid receptors in nasal mucosal cells, suppressing the transcription of inflammatory genes. This decreases the production of cytokines, chemokines, and other mediators that cause swelling and mucus production, leading to reduced nasal inflammation and symptom relief.

The appropriate dose of Mometasone Eg is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and the product label for the correct number of sprays per day.

Safety of Mometasone Eg in pregnancy or while breastfeeding has not been definitively established. Women who are pregnant, planning to become pregnant, or nursing should discuss potential risks and benefits with their healthcare provider before using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometasone Eg belongs to the same class as other nasal corticosteroids such as fluticasone and budesonide. It offers comparable anti‑inflammatory efficacy with a once‑daily dosing regimen for many patients, and its high receptor affinity may provide effective symptom control at low doses.

Mometasone Eg should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and heat sources to maintain its stability and potency.

Mometasone Eg is administered as a nasal spray. The patient should gently blow the nose, insert the spray tip into one nostril, close the opposite nostril, and press the pump while breathing in gently through the nose. The recommended number of sprays per day is set by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and increased intra‑ocular pressure that could affect vision. Patients should seek medical attention if they notice unusual bleeding, persistent nosebleeds, or visual changes.

Mometasone Eg should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections or recent nasal surgery until healing is complete.